Behavioral Health

Social anxiety disorder and specific phobias

Clinical Overview and When to Suspect Social Anxiety Disorder and Specific Phobias

— SAD: fear of scrutiny, negative evaluation, or humiliation in social/performance situations (speaking, eating, using public restrooms, meeting strangers).

— Specific phobia: fear cued by a circumscribed object/situation — animal, natural environment (heights, storms), blood-injection-injury (BII), situational (flying, enclosed spaces), or "other."

— Young adult avoiding classroom presentations, declining promotions, or refusing dating.

— Patient who no-shows for colonoscopy, MRI, or dental work — think situational phobia/claustrophobia.

— Pre-op patient who faints at venipuncture or refuses IV placement → BII phobia.

— Adolescent with school refusal, somatic complaints (abdominal pain, headache) on school days.

— Adult presenting with alcohol use before parties or work events — self-medication for SAD.

Board pearl: A patient who refuses cardiac catheterization specifically because of "needles and blood" — not the procedure risk — has BII phobia, not poor decisional capacity. Treat the phobia; do not invoke capacity evaluation.

Social anxiety disorder (SAD) and specific phobias are the two most common anxiety disorders in the US, with lifetime prevalence of ~12% and ~12–15% respectively, yet both are massively under-recognized in primary care.

Core construct: excessive, persistent (≥6 months) fear that is out of proportion to the actual threat, triggering avoidance and functional impairment.

When to suspect on Step 3:

Onset: SAD typically begins in early adolescence (median age 13); specific phobias often start in childhood (ages 7–10) but BII and situational subtypes can emerge in adulthood.

High comorbidity with major depression, other anxiety disorders, and alcohol use disorder — screen for all three when one is found.

Differentiate from normal performance anxiety: pathologic when there is avoidance, impaired work/school/relationships, or distress lasting ≥6 months.

Presentation Patterns and Key History

— Cognitive: anticipatory worry days to weeks before an event; post-event rumination ("everyone noticed I was sweating").

— Behavioral: avoidance of meetings, eating in front of others, dating, public restrooms ("paruresis"); reliance on "safety behaviors" (rehearsing scripts, alcohol, sitting near exits).

— Physical: blushing, tremor, sweating, tachycardia, dry mouth, voice quivering — autonomic activation specifically in social contexts.

— Performance-only subtype: anxiety limited to public speaking/performing; functions normally otherwise.

— Immediate, near-reflexive fear on exposure; often panic-like surge but cue-bound, not spontaneous.

— BII phobia uniquely: biphasic vasovagal response → initial sympathetic surge then bradycardia, hypotension, syncope. Other phobias cause tachycardia only.

— Active avoidance: driving hours to avoid a bridge, refusing elevators, declining MRI.

— "Do you avoid situations because you fear embarrassment or scrutiny?" (SAD)

— "Is your fear focused on one specific thing or situation?" (phobia)

— Duration ≥6 months, impairment, and not better explained by another disorder (panic disorder, PTSD, OCD, body dysmorphic disorder).

— Substance/medication review: caffeine, stimulants, albuterol, levothyroxine overreplacement, pseudoephedrine can mimic anxiety.

— Screen for alcohol use (CAGE/AUDIT-C) — SAD has ~50% comorbid AUD lifetime.

— Suicidality screen (PHQ-9 #9) in all anxiety presentations.

Key distinction: Panic disorder = unexpected, uncued panic attacks + worry about future attacks. SAD/specific phobia = panic-like symptoms only when cued by the feared stimulus. The cue-dependence is the diagnostic anchor.

SAD presentation patterns:

Specific phobia presentation patterns:

Key history questions (high-yield for Step 3 vignettes):

Validated screeners: Mini-SPIN (3-item) or Social Phobia Inventory (SPIN) for SAD; no widely used screener for specific phobia — diagnosis is clinical.

Physical Exam Findings (and Autonomic Assessment when relevant)

— Tachycardia, mild hypertension, diaphoresis, fine tremor, flushed face, hyperventilation.

— Cool clammy palms, dry mouth, voice tremor.

— No focal neurologic deficits, no thyromegaly, no exophthalmos — if present, pursue medical workup.

— Witnessed vasovagal syncope on venipuncture: bradycardia → pallor → diaphoresis → loss of consciousness, with rapid recovery supine.

— Distinguish from true cardiogenic syncope (no clear trigger, exertional, family history of sudden death) — these need cardiac workup, not phobia treatment.

— Thyroid: palpate gland, look for lid lag, tremor, hyperreflexia → check TSH.

— Cardiac: irregular rhythm (AF), murmurs, displaced PMI → ECG.

— Neurologic: postural tremor (essential tremor often misread as anxiety), gait, focal findings.

— Pulmonary: wheezing (asthma exacerbation can mimic panic).

— Skin: pheochromocytoma is rare but causes paroxysmal HTN + palpitations + headache + diaphoresis — check supine/standing BP if episodic.

Step 3 management: If a patient presents to clinic with "anxiety" but exam shows resting HR 130, lid lag, and weight loss, order TSH/free T4 before any psychiatric treatment — untreated hyperthyroidism mimics and worsens anxiety, and SSRIs will not fix it.

Anxiety disorders are clinical diagnoses; physical exam is primarily to exclude medical mimics, not confirm the disorder.

During or anticipating exposure (e.g., in the exam room if scrutiny-triggered):

BII phobia exam pearl:

Targeted medical mimic exam:

Vital sign pattern in pure anxiety: modest sinus tachycardia (90–110), normal or mildly elevated BP, normal SpO₂, normal temperature. Marked HTN (>180), SpO₂ <94%, or fever should redirect workup.

Mental status: alert, oriented, anxious affect, intact reality testing (phobias are ego-dystonic — patient recognizes the fear is excessive, distinguishing from delusional disorder).

Diagnostic Workup — Initial Labs and Medical Mimic Screen

— TSH — hyperthyroidism is the classic anxiety mimic; check in any new-onset adult anxiety, weight loss, tachycardia, or heat intolerance.

— CBC — anemia causing palpitations/fatigue.

— BMP — hypoglycemia, hypocalcemia (perioral tingling, Chvostek), electrolyte derangements.

— Glucose/HbA1c — recurrent hypoglycemia mimics panic.

— Urine drug screen — cocaine, methamphetamine, cannabis withdrawal, MDMA.

— Urine pregnancy in reproductive-age women before pharmacotherapy.

— ECG if palpitations, syncope, or before starting QT-prolonging agents (citalopram, escitalopram, hydroxyzine).

— Echocardiogram only if murmur or structural concern.

— Plasma/urine metanephrines if paroxysmal HTN + headache + diaphoresis (pheochromocytoma).

— 24-hour Holter for unexplained palpitations not reproduced in clinic.

— Brain MRI, EEG, cortisol — only with focal neuro findings or Cushingoid features.

— Lyme, autoimmune panels — not standard.

— Marked fear of ≥1 social situation involving possible scrutiny.

— Fear of negative evaluation/humiliation.

— Situation almost always provokes fear; actively avoided or endured with distress.

— Out of proportion; ≥6 months; clinically significant impairment.

Board pearl: A "panic attack" triggered only by seeing a dog is a specific phobia (animal type), not panic disorder. Panic disorder requires unexpected attacks plus persistent worry about future attacks.

Anxiety disorders require no confirmatory lab or imaging — DSM-5 criteria are clinical. Workup exists to rule out medical conditions and substances that mimic anxiety.

First-tier labs (order selectively based on history/exam, not reflexively):

Second-tier (if clinically indicated):

What you do NOT need routinely:

DSM-5 anchor for SAD:

DSM-5 anchor for specific phobia: same structural criteria but cue is a specific object/situation; subtype the cue (animal, natural environment, BII, situational, other).

Diagnostic Workup — Confirmatory Clinical Assessment and Comorbidity Mapping

— Liebowitz Social Anxiety Scale (LSAS) — 24-item, gold standard for SAD severity and treatment response; score ≥60 suggests generalized SAD.

— SPIN / Mini-SPIN — quicker primary care use; Mini-SPIN ≥6 is positive screen.

— GAD-7 — non-specific but useful for global anxiety burden tracking.

— PHQ-9 — mandatory in all anxiety patients (depression comorbidity ~40%).

— For specific phobia: no standard scale; document specific trigger, avoidance behaviors, and functional impact (missed medical procedures, job limitations, travel restrictions).

— Major depressive disorder — PHQ-9.

— Alcohol/substance use disorder — AUDIT-C, single-question screen.

— Other anxiety disorders — panic, GAD, agoraphobia.

— Avoidant personality disorder — pervasive pattern beyond social fear; substantial overlap with generalized SAD.

— Autism spectrum disorder — social discomfort here is from skill deficit/sensory issues, not fear of evaluation.

— Body dysmorphic disorder — fear is of being judged for a specific perceived defect.

— School/work performance, attendance.

— Relationships, dating, marriage.

— Medical avoidance (skipped Pap smear, colonoscopy, vaccinations).

— Substance use as self-treatment.

Key distinction: Avoidant personality disorder vs. generalized SAD — overlapping but APD involves a broader self-concept of inadequacy and is pervasive across all relationships including family. Many clinicians treat them as a severity spectrum; SSRIs help both.

Since there is no biomarker, "confirmation" = structured clinical interview + impairment assessment + comorbidity screen.

Severity and tracking instruments:

Comorbidity map to screen at diagnosis:

Functional impairment documentation (drives treatment intensity and disability determinations):

Risk Stratification and First-Line Management Logic

— Exposure-based CBT (in vivo exposure, systematic desensitization) is definitively first-line and often curative in a few sessions.

— Medications are not first-line and not generally effective for specific phobia.

— BII phobia exception: teach applied tension (tensing large muscle groups to raise BP and prevent syncope) — this is the specific evidence-based technique.

— Short-term benzodiazepine only as bridge for an unavoidable single exposure (e.g., emergent MRI) when CBT not feasible.

— Mild/performance-only: CBT alone, or as-needed propranolol 10–40 mg 30–60 min before performance (musicians, public speakers).

— Moderate–severe generalized SAD: SSRI or SNRI + CBT is gold standard; either alone is acceptable if patient prefers.

— Treatment-resistant: switch SSRI → SNRI, add CBT, consider augmentation; refer psychiatry.

— Benzodiazepines — risk of dependence, especially given high AUD comorbidity in SAD; reserve for short-term bridging.

— Buspirone — ineffective for SAD.

— Bupropion — ineffective and can worsen anxiety.

— SSRIs take 4–6 weeks for full effect; warn about initial activation/jitteriness in week 1–2.

— CBT typically 12–16 weekly sessions.

Step 3 management: A violinist with isolated performance anxiety before recitals — first-line is propranolol 20 mg PO 60 minutes before performance (after confirming no asthma, no bradyarrhythmia). Daily SSRI is overtreatment for performance-only subtype.

Treatment intensity is driven by (1) severity and impairment, (2) generalized vs. performance-only subtype, (3) patient preference, (4) comorbidities (especially depression and AUD).

Specific phobia — first-line is non-pharmacologic:

Social anxiety disorder — stepped care:

Avoid as monotherapy:

Patient education anchors:

Pharmacotherapy — First-Line Drug Regimens

— Paroxetine (FDA-approved): start 10 mg, target 20–60 mg. Watch sedation, weight gain, anticholinergic effects, discontinuation syndrome (short half-life), and pregnancy category concern (cardiac defects).

— Sertraline (FDA-approved): start 25–50 mg, target 50–200 mg. Best-tolerated; GI side effects most common.

— Fluoxetine: start 10–20 mg, target 20–60 mg. Long half-life → low discontinuation risk but more drug interactions (CYP2D6/3A4).

— Escitalopram: start 5–10 mg, target 10–20 mg; max 20 mg (QT prolongation; 10 mg max in >60 yo).

— Venlafaxine XR (FDA-approved): start 37.5–75 mg, target 75–225 mg. Monitor BP — dose-dependent HTN above 150 mg.

— Propranolol 10–40 mg PO 30–60 min pre-event; blunts tremor, tachycardia, voice quivering.

— Contraindications: asthma, decompensated HF, bradyarrhythmias, severe peripheral vascular disease.

— Not effective for generalized SAD.

Board pearl: Never combine an SSRI/SNRI with an MAOI; require a 14-day washout (5 weeks after fluoxetine due to long half-life) to prevent fatal serotonin syndrome.

SSRIs — first-line for generalized SAD:

SNRI — first-line alternative:

Start low, titrate slowly — anxious patients are exquisitely sensitive to activation; rapid titration causes treatment dropout.

Initial activation management: warn about jitteriness/insomnia week 1–2; can co-prescribe short course (≤4 weeks) of a benzodiazepine bridge in select cases.

Treatment trial: 8–12 weeks at therapeutic dose before declaring non-response.

Performance-only SAD — beta-blockers:

Second-line/adjuncts: other SSRIs (citalopram), MAOIs (phenelzine — historically very effective but tyramine/serotonin syndrome risk limits use), gabapentin, pregabalin.

Discontinuation: taper SSRIs over 4+ weeks; continue ≥6–12 months after remission, longer if recurrent.

Expanded Pharmacology and Psychotherapy Modalities

— Components: psychoeducation, cognitive restructuring, graded in vivo exposure, social skills training, video feedback.

— Exposure therapy is the active ingredient — patient builds a fear hierarchy and progressively confronts feared situations until anxiety habituates (extinction learning).

— Typically 12–16 sessions; group CBT is equally effective for SAD and lower cost.

— Virtual reality exposure is evidence-based for flying, heights, public speaking phobias.

— Systematic desensitization with relaxation pairing.

— One-session treatment (Öst protocol) — 2–3 hour single exposure session, ~80% response for animal/situational phobias.

— Applied tension for BII phobia — tense arms/legs/trunk for 10–15 sec, release, repeat; raises BP and prevents vasovagal syncope; teach before any required procedure.

— Clonazepam or lorazepam may be used short-term; avoid in patients with AUD, opioid use, elderly, or pregnancy.

— Limit to <4 weeks; never as monotherapy for SAD.

— Risk: dependence, cognitive impairment, falls, respiratory depression with opioids (FDA boxed warning).

— D-cycloserine to enhance exposure learning (research-level, not standard).

— Gabapentin 600–3600 mg/day, pregabalin 150–600 mg/day — modest SAD evidence.

— MAOIs (phenelzine) — most effective but tyramine dietary restriction.

CCS pearl: For an inpatient needing an emergent MRI who has severe claustrophobia, the CCS-correct sequence is: (1) trial of behavioral coaching + open MRI if available, (2) lorazepam 1–2 mg PO 30 min pre-scan as a single-time bridge, (3) outpatient referral for exposure-based CBT to prevent future delays.

Cognitive Behavioral Therapy (CBT) — the highest-yield non-drug intervention:

Specific phobia-specific techniques:

Benzodiazepines — careful use:

Augmentation/refractory options:

Combination logic: SSRI + CBT > either alone for moderate–severe SAD; for specific phobia, exposure therapy alone is sufficient.

Special Populations — Elderly and Renal/Hepatic Impairment

— Anxiety disorders are under-recognized in older adults; often somatized as GI complaints, dizziness, or insomnia.

— New-onset late-life anxiety should prompt workup for medical mimics first: hyperthyroidism, arrhythmia, COPD, heart failure, medication effect (steroids, bronchodilators, levothyroxine), early dementia, depression.

— SSRI choice: sertraline or escitalopram preferred (favorable drug-interaction profile).

— Escitalopram max 10 mg/day in age >60 (QT prolongation risk).

— Avoid paroxetine — strongly anticholinergic, sedating, falls and cognitive impairment (Beers criteria).

— Avoid benzodiazepines — Beers criteria; high risk of falls, hip fracture, delirium, cognitive decline, MVAs.

— Start at half the usual starting dose and titrate slowly ("start low, go slow").

— Monitor for SIADH/hyponatremia within 2–4 weeks of SSRI initiation, especially with thiazide co-prescription.

— Most SSRIs are hepatically metabolized — minimal dose adjustment.

— Venlafaxine: reduce dose by 25–50% in moderate–severe CKD.

— Gabapentin/pregabalin: significant renal adjustment required (eGFR <60).

— Lorazepam preferred benzodiazepine in renal disease (no active metabolites).

— Reduce SSRI/SNRI dose by 50% in moderate impairment; avoid in severe.

— Lorazepam, oxazepam, temazepam ("LOT") preferred — glucuronidation only, no oxidative metabolism.

— SSRI + NSAID/anticoagulant → GI bleeding risk; consider PPI.

— SSRI + tramadol/triptans/linezolid → serotonin syndrome.

— Paroxetine/fluoxetine inhibit CYP2D6 → reduces tamoxifen activation (avoid combination).

Board pearl: Hyponatremia in an elderly patient 2 weeks after starting sertraline is SSRI-induced SIADH until proven otherwise — check serum sodium, hold the SSRI, and switch to a non-SSRI option if recurrent.

Elderly patients (≥65 yo):

Renal impairment:

Hepatic impairment:

Polypharmacy alerts:

Special Populations — Pregnancy, Pediatrics, and Perinatal

— Untreated maternal anxiety is associated with preterm birth, low birth weight, and postpartum depression — do not reflexively discontinue medications.

— Sertraline is the preferred SSRI in pregnancy and lactation (lowest breast milk levels, extensive safety data).

— Avoid paroxetine in pregnancy — associated with cardiac malformations (especially first trimester); FDA Category D historically.

— Third-trimester SSRI exposure: small risk of neonatal adaptation syndrome (jitteriness, feeding difficulty, respiratory distress) and persistent pulmonary hypertension of the newborn (PPHN) — do not abruptly stop; coordinate delivery plan.

— CBT is first-line for mild–moderate cases during pregnancy; preferred over medication when feasible.

— Benzodiazepines: avoid in first trimester (cleft lip/palate signal, controversial); near delivery → floppy infant syndrome, withdrawal.

— Often presents as school refusal, selective mutism (early childhood SAD variant), somatic complaints.

— CBT is first-line for all severities in children.

— FDA-approved SSRIs for pediatric anxiety: fluoxetine (≥7), sertraline (OCD only), escitalopram (depression ≥12); off-label use is common and supported.

— Black box warning: SSRIs and suicidal ideation in patients <25 — discuss with family, monitor weekly first month.

— Selective mutism: a SAD variant in young children; treat with behavioral therapy ± SSRI (fluoxetine has best evidence).

Step 3 management: A 28-year-old in second trimester on paroxetine 40 mg for SAD — do not stop abruptly (discontinuation syndrome + relapse risk). Cross-taper to sertraline with OB and psychiatry coordination, continue CBT.

Pregnancy:

Lactation: sertraline and paroxetine have lowest infant serum levels; fluoxetine has long half-life and higher accumulation.

Pediatric/adolescent SAD and phobias:

Avoid in pediatrics: paroxetine (efficacy/safety concerns in youth), benzodiazepines (paradoxical disinhibition).

Complications and Adverse Outcomes

— Major depressive disorder — develops in 40–70% of SAD over time; SAD usually precedes MDD.

— Alcohol use disorder — SAD has ~2-3× increased risk; self-medication pattern (drinking before social events).

— Other substance use disorders — cannabis, benzodiazepine misuse.

— Suicidality — elevated risk, especially with comorbid depression and AUD.

— Functional impairment: lower educational attainment, unemployment, never-married status, social isolation.

— Medical avoidance: missed cancer screening, vaccinations, dental care, prenatal visits — leads to late-stage disease detection.

— BII phobia → avoidance of medical care, missed vaccinations, delayed diagnosis, refusal of needed procedures.

— Claustrophobia → inability to undergo MRI, CT in some, dental work, elevators.

— Dental phobia → severe periodontal disease, dental abscesses, endocarditis risk in valvulopathy.

— Flying phobia → occupational and family impairment.

— Driving phobia (situational) → unemployment in car-dependent regions.

— SSRI side effects: GI upset, sexual dysfunction (30–70% — major adherence issue), weight gain, insomnia, sweating, hyponatremia/SIADH, bleeding risk (especially with NSAIDs/anticoagulants), QT prolongation (citalopram, escitalopram).

— Serotonin syndrome — triad of mental status change, autonomic hyperactivity, neuromuscular hyperactivity (hyperreflexia, clonus).

— SSRI discontinuation syndrome — flu-like, "brain zaps," dizziness, mood lability; most severe with paroxetine and venlafaxine.

— Benzodiazepine dependence, falls, MVAs, cognitive impairment, paradoxical disinhibition in elderly and youth.

— Beta-blocker: bradycardia, bronchospasm, hypoglycemia masking in diabetes.

Key distinction: Serotonin syndrome (acute, hours, hyperreflexia/clonus, mydriasis) vs. NMS (subacute, days, rigidity, hyporeflexia, antipsychotic exposure). Both cause hyperthermia and autonomic instability — treatment differs (cyproheptadine vs. dantrolene/bromocriptine).

Untreated anxiety disorder complications:

Specific phobia complications:

Treatment-related adverse outcomes:

When to Escalate Care — Specialist Referral and Inpatient Triage

— Failure of ≥2 adequate SSRI/SNRI trials (8–12 weeks each at therapeutic dose).

— Severe comorbidity: bipolar disorder, psychosis, severe personality disorder.

— Active suicidal ideation with plan/intent.

— Pregnancy or perinatal complexity.

— Need for MAOI, ECT, or augmentation strategies.

— Diagnostic uncertainty (e.g., distinguishing SAD from autism, schizoid).

— Imminent suicide or homicide risk.

— Severe substance withdrawal (alcohol, benzodiazepines) requiring monitoring.

— Inability to perform basic self-care.

— Catatonia (rare in pure anxiety, but seen in severe comorbid depression).

— Suspected serotonin syndrome (hyperthermia, clonus, AMS) → discontinue serotonergic agents, IV fluids, benzodiazepines, cooling, cyproheptadine if severe; ICU if hyperthermia >41°C or rigidity.

— Severe benzodiazepine overdose with respiratory depression → flumazenil only if iatrogenic acute overdose in non-dependent patient (precipitates seizures in chronic users).

— Syncope with injury from BII reaction → ECG, orthostatics, head CT if head strike.

CCS pearl: For a patient presenting after intentional sertraline overdose: order ECG (QT), acetaminophen/salicylate levels (co-ingestion), basic labs, psychiatric consult, and 1:1 observation. Do not discharge until psychiatric clearance and safety plan documented.

Anxiety disorders are largely outpatient conditions; inpatient psychiatric admission is uncommon and driven by comorbidity, safety, or substance withdrawal.

Refer to psychiatry when:

Refer to psychologist/LCSW for CBT at diagnosis — early referral improves outcomes; do not wait for medication failure.

Inpatient psychiatric admission indications:

Emergency department/medical inpatient triggers:

Health system pearl: Use collaborative care models (PCP + embedded behavioral health + psychiatric consultant) — evidence-based for anxiety in primary care; covered under most value-based contracts.

Key Differentials — Same-Category (Anxiety Spectrum) Causes

— Recurrent unexpected panic attacks + ≥1 month of worry about future attacks or behavioral change.

— Key contrast: attacks are uncued (not tied to a specific stimulus).

— Treatment: SSRI + CBT; same first-line agents as SAD.

— Fear of ≥2 of: public transport, open spaces, enclosed spaces, crowds/lines, being outside home alone.

— Driven by fear of inability to escape or get help if panic-like symptoms occur — not fear of scrutiny.

— Often comorbid with panic disorder.

— Excessive worry about multiple domains (work, health, finances, family) ≥6 months.

— Physical symptoms: muscle tension, fatigue, sleep disturbance, irritability, concentration problems.

— Worry is pervasive, not cue-bound to social situations or specific objects.

— Fear of separation from attachment figures; can persist or emerge in adulthood (newer DSM-5 framing).

— Consistent failure to speak in specific social situations despite speaking elsewhere; pediatric variant strongly linked to SAD.

— Caffeine, stimulants, bronchodilators, decongestants, levothyroxine, corticosteroids, cannabis intoxication, alcohol/benzodiazepine withdrawal.

— Temporal relationship to substance use/withdrawal is the diagnostic anchor.

— Hyperthyroidism, pheochromocytoma, hypoglycemia, cardiac arrhythmia, COPD, PE.

Key distinction (the high-yield Step 3 grid):

— Cue is a social/performance situation → SAD

— Cue is a specific object/situation → specific phobia

— No cue (unexpected) → panic disorder

— Fear is of escape/help unavailability → agoraphobia

— Worry across multiple life domains → GAD

Panic disorder:

Agoraphobia:

Generalized anxiety disorder (GAD):

Separation anxiety disorder:

Selective mutism:

Substance/medication-induced anxiety disorder:

Anxiety due to another medical condition:

Key Differentials — Other-Category Causes

— Anxiety triggered by reminders of a specific traumatic event; includes intrusions, avoidance, negative cognitions, hyperarousal ≥1 month post-trauma.

— Specific phobia of trauma-related stimuli (e.g., fear of cars after MVC) — DSM hierarchy assigns PTSD if criteria met.

— Obsessions/compulsions; avoidance is driven by contamination, harm, symmetry, or taboo intrusive thoughts, not evaluation or specific external cue.

— Treatment: higher-dose SSRIs + ERP (exposure and response prevention).

— Preoccupation with perceived physical defect; social avoidance driven by shame about appearance, not general scrutiny — overlap with SAD common.

— Health-focused anxiety; differentiate from medical avoidance in BII phobia.

— Anhedonia, low mood, social withdrawal driven by lack of interest, not fear; often comorbid with SAD.

— Social difficulty stems from communication/sensory differences, not fear of evaluation; onset in early childhood with restricted interests, repetitive behaviors.

— Prefers solitude, no desire for social connection; SAD patients want connection but are afraid.

— Pervasive feelings of inadequacy across all relationships; substantial overlap with generalized SAD — many view as severity continuum.

— Hyperthyroidism, pheochromocytoma, carcinoid, hypoglycemia, mitral valve prolapse, paroxysmal arrhythmia, asthma, PE, withdrawal states.

— Anxiety in response to identifiable stressor within 3 months, resolves within 6 months of stressor cessation; doesn't meet full SAD/phobia criteria.

Board pearl: A patient afraid to leave home because they fear having a panic attack in public with no escape → agoraphobia. A patient afraid to leave home because they fear judgment by neighbors → SAD. The motivation for avoidance distinguishes them.

PTSD:

OCD:

Body dysmorphic disorder:

Illness anxiety/somatic symptom disorder:

Major depressive disorder:

Autism spectrum disorder:

Schizoid personality disorder:

Avoidant personality disorder:

Medical mimics:

Adjustment disorder with anxiety:

Secondary Prevention, Maintenance, and Long-Term Plan

— Continue SSRI/SNRI for 6–12 months after symptom remission for first episode.

— Indefinite/long-term treatment for: ≥3 episodes, severe baseline functioning, chronic course, strong family history, severe comorbidity.

— Taper over at least 4 weeks (longer for paroxetine and venlafaxine due to short half-life).

— CBT skills are durable — patients trained in CBT have lower relapse rates than medication-only.

— Booster CBT sessions every 3–6 months during medication taper.

— Identify early warning signs: increased avoidance, return of anticipatory worry, sleep disturbance, alcohol use uptick.

— Regular aerobic exercise — modest evidence for anxiety reduction; recommend 150 min/week moderate intensity.

— Limit caffeine to <400 mg/day; eliminate if anxiety-sensitive.

— Limit/eliminate alcohol — both worsens anxiety and risks AUD development.

— Sleep hygiene — anxiety and insomnia are bidirectional.

— Mindfulness-based stress reduction (MBSR) — modest evidence as adjunct.

— Cancer screening (Pap, mammogram, colonoscopy — BII patients particularly).

— Vaccinations (HPV, Tdap, influenza, COVID-19).

— Dental care.

— Reproductive health visits.

Step 3 management: A patient with SAD in stable remission on sertraline for 14 months asks about stopping. If first episode, mild–moderate severity, no current stressors: taper over 4–6 weeks while continuing CBT skills, schedule follow-up at 1, 3, 6 months post-taper.

Duration of pharmacotherapy:

Relapse prevention:

Lifestyle and adjunctive measures:

Catch-up preventive care after diagnosis — anxiety-disorder patients often have deferred preventive services:

Comorbid AUD: address simultaneously — naltrexone or acamprosate may be added; treating only the anxiety while AUD persists leads to relapse of both.

Patient self-management resources: ADAA, NAMI, evidence-based self-help workbooks, validated apps (with caveats about regulation/privacy).

Follow-Up, Monitoring Parameters, and Counseling Cadence

— Week 1–2 follow-up (in-person or telehealth) after starting SSRI — assess activation, tolerability, suicidal ideation (especially <25 yo black box).

— Week 4 follow-up — initial response often partial; adjust dose if no improvement.

— Week 8–12 — assess full response; if <50% improvement, consider dose increase, augmentation, or switch.

— Monthly visits; track with LSAS, SPIN, or GAD-7 at each visit.

— Reinforce CBT skills, address side effects (especially sexual dysfunction — leading cause of nonadherence).

— Screen for emerging depression (PHQ-9) and substance use.

— Visits every 3 months; longer intervals if stable.

— Annual labs not routinely required for SSRIs in healthy adults; check sodium in elderly or with new symptoms.

— ECG if on citalopram >20 mg, escitalopram >10 mg (>60 yo), or new cardiac symptoms.

— Sexual dysfunction: ask directly at each visit; options include dose reduction, switch (bupropion is sexually neutral but not first-line for SAD), or adjunct (sildenafil, bupropion add-on).

— Weight: annual BMI and metabolic check if on paroxetine.

— Bleeding: caution with NSAIDs/anticoagulants; co-prescribe PPI if high risk.

— Falls in elderly: medication review.

— CBT typically 12–16 sessions; track session attendance and homework completion.

— Booster sessions at 3, 6, 12 months for maintenance.

— Document medications, doses, current symptom scores at every transition.

— Coordinate when patient transfers between PCP, psychiatrist, therapist.

CCS pearl: When following an anxiety patient in CCS, advance the clock in 1–2 week increments during medication titration to capture activation and early response, then monthly during maintenance — clock granularity matches clinical decision points.

Initial treatment phase (weeks 0–8):

Stabilization phase (months 3–6):

Maintenance phase (≥6 months):

Monitoring side effects:

Psychotherapy follow-up:

Care transitions:

Ethical, Legal, and Patient Safety Considerations

— A patient refusing a procedure due to a phobia retains decisional capacity if they understand the risks of refusal. Phobia is not incapacity. Treat the phobia (anxiolytic premedication, exposure preparation, behavioral support) rather than override consent.

— BII phobia is a classic Step 3 scenario: a patient refuses needed IV access or surgery citing needle fear — document capacity discussion, offer accommodations (topical anesthetic, distraction, lorazepam premedication, applied tension training).

— When initiating SSRIs in patients <25, document discussion with patient (and family/guardian if minor) of the increased suicidal ideation risk and the monitoring plan.

— Adolescents may seek mental health treatment with varying consent rules by state; know your state's minor consent statute.

— Confidentiality is generally maintained except for safety threats (suicide, homicide, abuse).

— Suspected child or elder abuse, intimate partner violence (state-dependent for IPV), and credible threats of harm to identified third parties (Tarasoff duty to warn/protect).

— Counsel patients about sedation risk from benzodiazepines and initial SSRI activation; document the counseling. Many states require physician reporting of impairment-related driving risk (varies).

— Severe SAD may qualify under ADA for reasonable accommodations (e.g., presentations via written format). Avoid certifying disability prematurely — emphasize treatment first.

— Highest-risk handoff in anxiety care = hospital discharge of a patient newly started on SSRI with comorbid depression. Ensure 1-week outpatient follow-up, medication reconciliation, crisis line provided, lethal-means counseling (especially firearms in suicidal patients).

Board pearl: A BII-phobic adult refusing chemotherapy port placement has full capacity; the ethical answer is not a capacity evaluation but a multidisciplinary phobia-management plan with premedication and behavioral support.

Informed consent and decisional capacity:

Black box warning disclosure:

Confidentiality and minors:

Mandatory reporting:

Driving safety:

Workplace and disability:

Transition-of-care risk:

Avoid coercive interventions — restraint or forced medication for pure anxiety presentations is rarely justified and ethically fraught.

High-Yield Associations and Rapid-Fire Clinical Facts

Key distinction: SAD asks "Will I be judged?" Specific phobia asks "Will this thing harm me?" Panic disorder asks "Will I have another attack?" Agoraphobia asks "Can I escape if something goes wrong?" GAD asks "Will everything in my life fall apart?"

Lifetime prevalence: SAD ~12%, specific phobia ~12–15% (US adults).

Median age of onset: SAD 13 years; specific phobia 7–10 years.

Female:male ratio: ~1.5–2:1 for both; women more likely to seek treatment.

Most common specific phobia subtypes: animal > natural environment > situational > BII.

BII phobia uniquely produces biphasic vasovagal response → bradycardia/syncope; treat with applied tension.

Propranolol — first-line for performance-only SAD; ineffective for generalized SAD.

Paroxetine, sertraline, venlafaxine XR — only FDA-approved agents for SAD.

Avoid paroxetine in pregnancy (cardiac malformations) and in elderly (anticholinergic, Beers).

Escitalopram max 20 mg generally, 10 mg in age >60 — QT prolongation.

Sertraline — preferred SSRI in pregnancy and lactation.

SSRI sexual dysfunction — 30–70%; major cause of nonadherence.

SSRI discontinuation syndrome — worst with paroxetine and venlafaxine (short half-life); fluoxetine essentially self-tapers.

SAD comorbidities (memorize): MDD ~50%, AUD ~50%, other anxiety disorders ~50%.

Treatment trial duration: 8–12 weeks at therapeutic dose before declaring non-response.

CBT for specific phobia: often curative in 1–5 sessions (Öst one-session protocol for animal/situational).

Virtual reality exposure: evidence-based for flying, heights, public speaking.

MAOI washout: 14 days (5 weeks for fluoxetine).

Buspirone and bupropion: not effective for SAD.

Selective mutism: pediatric SAD variant; treat with behavioral therapy ± fluoxetine.

Generalized SAD ≈ avoidant personality disorder on a severity spectrum — both respond to SSRIs + CBT.

Board Question Stem Patterns

Step 3 management: When the stem describes avoidance of a specific medical procedure, the test wants you to treat the phobia and accommodate the patient (premedication, exposure, applied tension for BII) — never the answer to "respect refusal and discharge" or "obtain capacity evaluation."

Classic SAD stem: "A 24-year-old graduate student avoids class presentations, declines a teaching assistantship, and drinks two beers before social events. Symptoms began at age 14. Physical exam normal." → Generalized SAD; first-line SSRI (sertraline, paroxetine) + CBT; screen for AUD.

Performance-only SAD stem: "A 35-year-old attorney has tremor and tachycardia only when giving courtroom arguments; functions normally otherwise." → Propranolol 20 mg PO 60 min pre-event; confirm no asthma.

BII phobia stem: "A 30-year-old man faints during routine blood draws; refuses recommended colonoscopy due to fear of IV needles." → Specific phobia, BII type; teach applied tension, refer for exposure therapy; do NOT question decisional capacity.

Specific phobia stem (animal): "An 8-year-old refuses to go outdoors after seeing a dog 6 months ago; cries on exposure." → Specific phobia, animal type; CBT with graded exposure first-line; SSRI not indicated.

Mimic stem: "A 45-year-old woman with 'anxiety attacks,' weight loss, tachycardia, fine tremor, and warm moist skin." → Check TSH; treat hyperthyroidism, not anxiety.

Distinguishing stem: "Recurrent panic attacks without identifiable trigger + 1 month of worry about future attacks." → Panic disorder, not SAD/phobia.

Pregnancy stem: "32-year-old at 10 weeks gestation on paroxetine 30 mg for SAD." → Cross-taper to sertraline; do not stop abruptly; continue CBT.

Elderly stem: "72-year-old started on sertraline; presents 2 weeks later confused with Na 124." → SSRI-induced SIADH; hold drug, fluid restrict, evaluate.

Comorbidity stem: SAD patient with "drinks 6 beers nightly to relax for next-day work." → Treat both SAD (SSRI + CBT) and AUD (naltrexone, MI).

Ethics stem: Patient refuses needed surgery due to needle phobia. → Capacity intact; offer premedication and behavioral support, not capacity override.

Refractory stem: "Adequate trials of sertraline and venlafaxine without response." → Refer to psychiatry; consider MAOI (phenelzine) or augmentation.

One-Line Recap

Social anxiety disorder and specific phobias are highly prevalent, cue-bound anxiety disorders best treated with exposure-based CBT first-line, with SSRIs/SNRIs (sertraline, paroxetine, venlafaxine) added for generalized SAD, propranolol for performance-only SAD, and applied tension uniquely for blood-injection-injury phobia.

— Specific phobia → exposure-based CBT alone (often curative in 1–5 sessions).

— Performance-only SAD → propranolol pre-event (contraindications: asthma, bradyarrhythmia).

— Generalized SAD → SSRI (sertraline, paroxetine) or SNRI (venlafaxine XR) + CBT, 8–12 week trial, continue 6–12 months after remission.

— BII phobia → applied tension + exposure; never withhold needed procedures — premedicate and accommodate.

Board pearl: If the vignette gives you a cue that triggers the fear, the diagnosis is SAD or specific phobia — never panic disorder. The cue is the entire game.

Diagnostic anchor: cue-bound fear (social scrutiny = SAD; specific object/situation = phobia) ≥6 months with avoidance and impairment; rule out hyperthyroidism, stimulant/substance use, and panic disorder/GAD/agoraphobia before committing to diagnosis.

First-line treatment hierarchy:

High-yield safety pearls: avoid paroxetine in pregnancy and elderly; sertraline preferred in pregnancy/lactation; benzodiazepines short-term bridge only (Beers in elderly, dependence risk, AUD comorbidity); SSRIs cause SIADH in elderly and discontinuation syndrome (taper ≥4 weeks); MAOIs require 14-day washout.

Step 3 systems thinking: aggressively screen for and treat comorbid MDD and AUD (each ~50% lifetime), catch up deferred preventive care (cancer screening, vaccinations, dental), use collaborative care models in primary care, and remember that phobia is not incapacity — accommodate the patient and treat the disorder rather than override consent or label as nonadherent.